Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

594.25 +5.99 (+1.02%)
Streaming Delayed Price Updated: 1:48 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,166,815
Open 589.00
Bid (Size) 594.14 (2)
Ask (Size) 594.37 (3)
Prev. Close 588.27
Today's Range 584.77 - 596.42
52wk Range 302.14 - 629.97
Shares Outstanding N/A
Dividend Yield 0.76%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pharma Giant Eli Lilly's Shareholder Bonanza: Announces Hefty 15% Dividend Hike For Q1
Eli Lilly and Company (NYSE: LLY) has boosted its quarterly dividend by an impressive 15%, announcing a payout of $1.30 per share  
Via Benzinga
Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?
These drugs address a rapidly growing market. 
Via The Motley Fool

Performance

YTD
+62.81%
+62.81%
1 Month
-0.95%
-0.95%
3 Month
+3.67%
+3.67%
6 Month
+33.34%
+33.34%
1 Year
+59.76%
+59.76%

More News

Read More
Challenging the Magnificent 7: 3 Stocks on the Rise
Via InvestorPlace
Topics Stocks
Exposures US Equities
Will There Be A Recession In 2024?
Via Talk Markets
Topics Economy
Exposures Economy
Neuropsychiatric Disorders and Treatment Market Projected to Show Strong Growth: Astrazeneca, AviadoBio, Astellas Pharma
Via SBWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Pictures Of Lilly
Via Talk Markets
Eli Lilly's Options Frenzy: What You Need to Know
Via Benzinga
What the Options Market Tells Us About Eli Lilly
Via Benzinga
Better Large-Cap Growth Fund: Schwab U.S. Large-Cap Growth or Vanguard Growth Index Fund?
Via The Motley Fool
Should You Buy Eli Lilly Stock Now or Wait for a Dip?
Via The Motley Fool
Which Stock Is More Likely to Help You Retire as a Millionaire: AbbVie or Eli Lilly?
Via The Motley Fool
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
Via Benzinga
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
Via Benzinga
1 Monster Dividend Stock Growth Investors Should Load Up On Right Now
Via The Motley Fool
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Via Benzinga
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
Via Investor's Business Daily
Ozempic vs. Mounjaro:: Battle of the bulge
Via MarketBeat
Exposures Product Safety
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
Via The Motley Fool
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
Via MarketBeat
Topics Bonds
Exposures Debt Markets
FDA Grants Second Conditional Approval For Eli Lilly's Rare Blood Cancer Drug
Via Benzinga
Exposures Product Safety
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
Via Benzinga
3 No-Brainer Growth Stocks to Buy in December
Via The Motley Fool
Pfizer Tumbles After Abandoning Weight-Loss Pill
Via Talk Markets
An Important History Lesson for Gene-Editing Investors
Via The Motley Fool
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.